Keros Therapeutics (NASDAQ:KROS) Shares Down 3.7% – Time to Sell?

Keros Therapeutics, Inc. (NASDAQ:KROS) fell 3.7% during mid-day trading on Thursday . The stock traded as low as $20.13 and last traded at $20.0680. 63,757 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 934,736 shares. The stock had previously closed at $20.83.

Analyst Upgrades and Downgrades

KROS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday. TD Cowen raised Keros Therapeutics to a “hold” rating in a research note on Friday. Wells Fargo & Company reduced their price objective on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Wedbush upped their target price on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Finally, Zacks Research upgraded Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.38.

Keros Therapeutics Trading Up 0.6%

The stock has a market cap of $617.32 million, a price-to-earnings ratio of 13.16, a price-to-earnings-growth ratio of 0.24 and a beta of 0.89. The business has a 50 day simple moving average of $17.36 and a two-hundred day simple moving average of $15.60.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The company had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. During the same period in the prior year, the company earned ($1.41) earnings per share. The firm’s revenue was up 3585.6% compared to the same quarter last year. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new position in shares of Keros Therapeutics during the third quarter worth $47,000. Tower Research Capital LLC TRC lifted its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. CWM LLC grew its position in shares of Keros Therapeutics by 87.5% in the 2nd quarter. CWM LLC now owns 5,000 shares of the company’s stock valued at $67,000 after purchasing an additional 2,333 shares during the period. SG Americas Securities LLC bought a new stake in Keros Therapeutics during the 3rd quarter worth approximately $103,000. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Keros Therapeutics by 29.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after buying an additional 1,892 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.